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Summary
Objective: To evaluate the relationship between central obesity, hyperinsulinemia and arterial hypertension with left 
ventricular mass and geometry in women.
Methods: This study included 70 women (35-68 years), divided into four groups according to the presence of central 
obesity and hypertension. Visceral fat area was determined. Blood glucose and plasma insulin were determined before 
and two hours after an oral 75g glucose load, and the patients were submitted to cardilogical evaluation.
Results: Compared to NT-OB, HT-OB presented higher levels of plasma insulin at 2h-OGTT (127.5 ± 73.0 vs 86.8 ± 
42.7 µU/ml; p=0.05) and reduced E wave/A wave ratio (E/A) (0.8 ± 0.1 vs 1.2 ± 0.3; p < 0.05). Compared to NT-NO, HT-
NO showed higher insulin levels before glucose load (7.46 ± 3.1 vs 4.32 ± 2.1 µU/ml; p < 0.05), higher HOMAr (1.59 ± 
0.72 vs 0.93 ± 0.48 mmol.mU/l²; p=0.006), higher leptin level (19.1 ± 9.6 vs 7.4 ± 3.5 ng/ml; p=0.028), greater VF area 
(84.40 ± 55.7 vs 37.50 ± 23.0 cm²; p=0.036), increased IVSTd (9.6 ± 1.2 vs 8.2 ± 1.7 mm; p <0.05) and (LVM/height) 
(95.8 ± 22.3 vs 78.4 ± 15.5 g/m; p < 0.05). Multiple linear regression analysis showed age, BMI and fasting glucose as 
determinants on LVM/height (R² = 0.59; p < 0.05).
Conclusion: Our results indicate an association among hypertension, central obesity and left ventricular hypertrophy 
through increases in sympathetic activity and insulin resistance. (Arq Bras Cardiol 2007;89(2):77-82)
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hypertrophy7. It has been reported that while hypertensive non-
obese patients show concentric left ventricular hypertrophy 
due to an increase in afterload10, obese patients, even the 
normotensives, show eccentric left ventricular hypertrophy 
due to an increase in preload. Hypertensive obese patients 
may present both these mechanisms.
The aim of this study was to further evaluate the relation 
between central obesity, hyperinsulinemia and hypertension 
with left ventricular mass and geometry in women.
Methods
We studied 70 women, from August 2001 to August 2003, 
ages ranging from 35-68 years, divided into 4 groups: NT-NO 
(normotensive non-obese/N=17), NT-OB (normotensive 
obese/N=18), HT-NO (hypertensive non-obese/N=18) and 
HT-OB (hypertensive obese/N=17). All were recruited from 
the  obesity and hypertension clinics of the Federal University 
of São Paulo and HSPE. Written informed consent was 
obtained from all participants, and the study was approved 
by the Institutional Ethics Committee. Central obesity was 
GHILQHG DVZHLJKW .J E\ KHLJKW PHWHUV VTXDUHG 
Kg/m² and waist circumference > 88 cm. Hypertension was 
GHILQHGDVV\VWROLFRUGLDVWROLFEORRGSUHVVXUH[PP
Hg or by self -reported use of antihypertensive medications. 
Exclusion criteria were self-reported diabetes and cardiac, 
hepatic and renal dysfunctions. The same observer measured 
weight, height and waist and hip circumferences. Arterial 
Introduction
Obesity, now recognized as an independent risk factor for 
cardiovascular disease (CVD), is strongly associated with other 
risk factors, including hypertension1-3. Complex mechanisms 
link increasing body weight with increasing blood pressure. 
Upper-body obesity, as compared to lower-body obesity, is 
most closely associated with obesity-related hypertension, 
and hyperinsulinemia has been suggested to be involved in 
the genesis of arterial hypertension in obese individuals2,3.
In the Framingham Study, for every 10 lb  weight gain (1 lb 
~ 0,453 Kg), systolic blood pressure increased , on average, 
4.5 mm Hg4. Some suggest that leptin may also increase 
blood pressure5,6.
As demonstrated by some investigators7-9, hypertensive obese 
patients show anatomic and hemodynamics abnormalities due 
to excess weight, including increase in intravascular volume, 
with enlargement of the vascular bed, as well as increases in 
heart rate and cardiac output.
It has been suggested that excessive oxygen consumption, 
due to higher metabolism in increased adipose tissue, 
associated with hypervolemia, contributes to left ventricular 
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blood pressure was taken after a five-minute rest in the sitting 
position, with a sphygmomanometer using an appropriate cuff 
size for arm circumference. The mean of two measurements 
was considered.
No patient used any antihypertensive medication for at 
least seven days prior to the study. After a 12-hour fast, serum 
glucose (glucose oxidase/Hitashi analyzer) and serum insulin 
(Auto Delfia, Perkin Elmer) were determined at 0 and 120 
minutes after a 75g oral glucose load. Fasting leptin (Linco 
Research, USA) was measured. 
Patients were submitted to electrocardiogram (Dixtal), 
and 24 h-ambulatory blood pressure monitoring (Spacelabs, 
Redmond, WA) registered blood pressure every 15 minutes 
during daytime (awake hours) and every 20 minutes during 
nighttime (sleep hours), based on the patients’ report on their 
activities during day and night. Blood pressure fall during sleep 
¨%3ZDVFDOFXODWHGE\GLYLGLQJWKHGLIIHUHQFHEHWZHHQPHDQ
awake systolic blood pressure and mean sleep systolic blood 
SUHVVXUHE\PHDQDZDNHV\VWROLFEORRGSUHVVXUH¨%3 PHDQ
awake SBP – mean sleep SBP x100/mean awake SBP).
Echocardiogram was performed, by the same examiner, at 
rest, with the patient at steady state in the left lateral position, 
using a 2.5 MHz transducer. Two-dimensional guided M-
mode measurements of left ventricular diastolic diameter 
(LVDD), diastolic interventricular septal thickness (IVSTd) 
and diastolic left ventricular posterior wall (LVPWd) were 
measured according to the recommendations of the American 
Society of Echocardiography11. Left ventricular mass (LVM) was 
estimated by Devereux’s formula12 and corrected by height 
/90KHLJKW7KHFXWRIIYDOXHRI/90KHLJKWJPZDV
adopted for the diagnosis of left ventricular hypertrophy13-16.
The E wave/A wave ratio (E/A) was used as an indicator of 
diastolic function. We used left ventricular mass corrected 
by body surface (LVMI) and relative posterior wall thickness 
(RPWT), which is the ratio between diastolic left ventricular 
posterior wall (LVPWd) and left ventricular diastolic diameter 
(LVDD) multiplied by 2.0 (LVPWd/LVDD x 2.0) to assess 
ventricular geometry17. Eccentric hypertrophy is defined 
E\/90,JPòDQG53:7ZKLOH FRQFHQWULF
K\SHUWURSK\LVGHILQHGE\53:7
Visceral fat area (density -50 to -250 HU) was obtained 
by computed tomography (Picker International), at the L4-L5 
level, expressed in cm².
Statistical analyses were performed using SPSS 12.0, and 
significance level was set as A = 0.05 (p < 0.05). We used 
ANOVA and Kruskal-Wallis for comparisons among the four 
groups. Fisher and Chi-Square were used to analyse nominal 
variables. Student’s and Mann-Whitney tests were used to 
compare two groups. Correlations were analysed through 
Pearson correlation coefficients. Multiple linear regression 
analysis was used to determine the influence of age, fasting 
and 2h- blood glucose, 2h- plasma insulin, BMI, VF and sleep 
and awake SBP on LVM/ height.
Results
Clinical, laboratorial and tomographic findings are shown in 
Table 1. Blood pressure measurements are shown in Table 2.
Only 57 % of all hypertensive patients were using 
antihypertensive medication up to seven days before 
evaluation. Hypertensive non-obese and hypertensive obese 
patients were using angiotensin-converting enzyme inhibitors 
(16.6% and 29%), hydrochlorothiazide (16.6% and 23.5%) and 
calcium channel blockers (5.5% and 23.5%), respectively.
The NT-OB and HT-OB groups showed similar LVM/ height 
values, which were higher than those of the NT-NO group 
(107.2 ± 30.7 and 109.1 ± 26.0 g/m), but did not differ 
from the HT-NO group (95.8 ± 22.3 g/m) (Table 3). LVM/
height values detected LVH in 36.51% (1.6% in the NT-NO, 
12.7% in the NT-OB, 11.1% in the HT-NO and 11.1% in the 
HT-OB) of the group as a whole. In the entire group, 16.0% 
showed eccentric hypertrophy and 8.0% showed concentric 
hypertrophy, and the proportions of patients with one or other 
form of hypertrophy in the four groups were very similar.
Table 1 - Clinical, tomographic and laboratory parameters according to the groups
NT-NO NT-OB HT-NO HT-OB
Age (years) 46.6 ± 9.1 47.3 ± 5.0 52.6 ± 11.0 50.5 ± 5.1
BMI (Kg/m²) 23.0 ± 2.2 36.0 ± 5.1 *‡ 23.8 ± 2.3 36.9 ± 5.8 *‡
Waist (cm) 71.3 ± 7.8 100.3 ± 13.2 *‡ 74.5 ± 9.9 101.8 ± 12.2 *‡
WHR 0.8 ± 0.01 0.9 ± 0.06 * 0.8 ± 0.06 0.9 ± 0.07 *
VF (cm²) 37.5 ± 23.0 115.3 ± 57.4 * 84.4 ± 55.7 * 127.7 ± 32.0 *
Gluc 0’(mg/dl) 82.6 ± 9.1 95.9 ± 9.9 * 86.7 ± 6.0 # 93.6 ± 13.0 *‡
Gluc120’ (mg/dl) 87.1 ± 29.0 132.8 ± 28.5 * 111.9 ± 27.4 *# 138.7 ± 49.2 *‡
Insul 0’(µU/ml) 4.32 ± 2.1 17.6 ± 7.5 *‡ 7.46 ± 3.1 * 16.8 ± 8.7 *‡
Insul120’(µU/ml) 34.7  ± 27.3 86.8 ± 42.7 *‡ 49.9 ± 25.3 127.5 ±73.0 *#‡
HOMA r 0.93 ± 0.48 3.96 ± 1.65 *‡ 1.59 ± 0.72 * 4.06 ± 2.39 *‡
Leptin (ng/ml) 7.4 ± 3.5 21.4 ± 10.1 * 19.1 ± 9.6 * 24.2 ± 13.5 *
* p<0.05 vs NT-NO; # p<0.05 vs NT-OB; ‡ p<0.05 vs HT-NO. HOMA r index - mmol.mU/l²); WHR - waist-to-hip ratio; VF - visceral fat area.
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Table 2 - Blood pressure measurements (office and 24h-ABPM) in the groups
NT-NO NT-OB HT-NO HT-OB
O-SBP (mm Hg) 116,5 ± 7,1 125,6 ± 8,8 * 137,8 ± 14,3 *# 147,9 ± 13,5*#‡
O-DBP (mm Hg)  75,8 ± 3,9 80,6 ± 6,5 * 86,6 ± 9,4 # 96,5 ± 6,5 *#‡
O-HR  (bpm) 78,0 ± 4,7 80,3 ± 3,6 75,9 ± 8,7 § 80,5 ± 3,9 
24h-SBP 115,9 ± 12,1 118,0 ± 5,5 133,3 ± 12,2 *# 143,7 ± 17,3
24h-DBP 71,8 ± 9,1 71,4 ± 5,5 85,4 ± 8,8 *# 86,5 ± 14,5 *#
24h-HR (bpm) 73,9 ± 8,3 78,4 ± 10,1 77,2 ± 9,7 85,3 ± 10,9 ‡
ASBP (mm Hg) 118,3 ± 12,8 120,9 ± 5,5 136,3 ± 13,0 *# 143,5 ± 16,8 *#
ADBP (mm Hg) 74,4 ± 9,5 74,3 ± 6,2 88,5 ± 9,4 *# 87,5 ± 14,4 *#
A-HR (bpm) 76,2 ± 8,4 83,1 ± 9,7 * 80,9 ± 10,9 85,9 ±  9,3 *
SSBP (mm Hg) 107,5 ± 9,9 108,9 ± 8,4 124,7 ± 11,9 *# 133,8 ± 14,8 *#
SDBP (mm Hg) 63,3 ± 7,7 62,3 ± 5,8 76,7 ± 8,4 *# 75,3 ± 11,8 *#
Sleep-HR (bpm) 66,5 ± 8,8 70,6 ± 9,6 67,9 ± 9,3 74,7 ± 8,4 *‡
Nocturnal dip < 10% (%) 31% 50% 60% 67%
* p<0.05 vs NT-NO; # p<0.05 vs NT-OB; ‡ p<0.05 vs HT-NO; § p=0.05 vs NT-OB. O-SBP/O-DBP - office systolic/diastolic blood pressure measure; 
O-HR - office heart rate; ASBP - awake systolic blood pressure; ADBP - awake diastolic blood pressure; SSBP - sleep systolic blood pressure; SDBP - sleep 
diastolic blood pressure.
Table 3 - Echocardiographic and electrocardiographic parameters according to the groups
NT-NO NT-OB HT-NO HT-OB
LA (mm) 30.9 ± 3.3 35.6 ± 4.0 * 33.7 ± 3.4 * 35.7 ± 5.2 *
AO (mm) 30.4 ± 2.4 30.1 ± 2.2 31.1 ±  3.2 33.4 ± 4.0 *#
IVSTd (mm) 8.2 ± 1.7 10.1 ± 1.5 * 9.6 ± 1.2 * 10.1 ± 1.1 *
LVPWd (mm) 8.7 ± 1.9 10.1 ± 3.8 9.2 ± 1.2 9.8 ± 1.3
IVSTd/LVPWd 0.9 ± 0.12 1.0 ± 0.2 * 1.0 ± 0.1 * 1.0 ± 0.1 *
LVDD (mm) 43.6 ± 2.8 45.6 ± 4.3 44.6 ± 3.9 46.0 ± 4.7
LVM (g) 122.4 ± 24.0 167.7 ± 48.2 * 152.8 ± 36.7 * 173.4 ± 43.6 *
LVMI (g/m²) 78.6 ± 13.8 91.4 ± 23.4 94.0 ± 22.9 91.4 ± 20.5
LVM/height (g/m) 78.4 ± 15.5 107.2 ± 30.7 * 95.8 ± 22.3 * 109.1 ± 26.0 *
E wave/A wave 1.4 ± 0.6 1.2 ± 0.3 1.1 ± 0.4 0.8 ± 0.1 *#‡
EF (%) 0.66 ± 0.06 0.66 ± 0.06 0.66 ± 0.07 0.67 ± 0.07
PR interval (ms) 145.9 ± 18.0 155.6 ± 18.8 155.3 ± 20.7 164.3 ± 11.6 *
QTc (s) 0.38 ± 0.03 0.39 ± 0.03  0.39 ± 0.02 0.40 ± 0.02 *
* p< 0.05 vs NT-NO; # p< 0.05 vs NT-OB; ‡ p< 0.05 vs HT-NO. LA - left atrial diameter; AO - aorta  diameter; IVSTd - diastolic interventricular septum 
thickness; LVPWd - diastolic left ventricular posterior wall thickness; LVDD - left ventricular diastolic diameter; LVM - left ventricular mass; LVMI - left 
ventricular mass index; LVM/height - left ventricular mass by height; EF - ejection fraction.
Plasma insulin values two hours after glucose load were 
higher in the HT-NO and HT-OB groups (49.9 ± 25.3 and 
127.5 ± 73.0 µU/ml), compared with NT-NO and NT-OB 
groups (34.7 ± 27.3 and 86.8 ± 42.7 µU/ml), respectively. 
The HT-NO group showed a tendency towards higher blood 
glucose level (111.9 ± 27.4 vs 87.1 ± 29.0 mg/dl; p = 0.057) 
at 2h-OGTT than the NT-NO group.
ECG analysis showed that QRS intervals were similar in all 
four groups, whereas  PR and QTc intervals were longer in 
the HT-OB than in the NT-NO group (Table 3).
Multiple linear regression analysis, with LVM/height as 
the dependent variable, and with age, BMI, fasting glucose, 
2h- blood glucose, 2h- plasma insulin, VF, awake and sleep 
systolic BP (SBP) as independent variables, showed that only 
age, fasting glucose and BMI were determinants of LVM/height 
(R²=0.59; p<0.05; Backward).
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Positive correlations were found between sleep systolic 
blood pressure (SSBP) and 2h- plasma insulin levels (r = 0.38; 
p = 0.01) and between sleep heart rate and 2h- blood glucose 
values (0.43; p< 0.01).
Mean values of LVM/height and E/A ratio in the groups are 
shown in Figures 1 and 2.
Discussion
Obesity and arterial hypertension are classical components 
of the metabolic syndrome2,3,8,18,19. Some authors have 
shown an association between obesity, as well as arterial 
107.2 ± 30.7*
Fig. 1 - Mean LVM/height in the groups.
78.4 ± 15.5
95.8 ± 22.3* 
109.1 ± 26.0*
Fig. 2 - Mean  E/A  ratio  in  the  groups. * p < 0.05 vs NT-NO; # p < 0.05 vs NT-OB; ‡ p < 0.05 vs HT-NO.
*# ‡ p < 0,05
hypertension, and left ventricular hypertrophy, increasing 
cardiovascular risk10,16,19.
Hyperinsulinemia has been considered the link 
between obesity, arterial hypertension and  type 2 diabetes 
through increases in adrenergic tonus and in renal sodium 
reabsorption2,18,20-23.
In our study, mean systolic and diastolic blood pressures 
were higher in  hypertensive obese women than in  hypertensive 
non-obese women, and these differences were also associated 
with increased heart rate during sleep and higher plasma 
insulin levels. In addition, a reduced nocturnal blood pressure 
fall was observed in hypertensive obese patients, and a positive 
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Conclusion
Our results indicate that hypertension and central obesity 
are causes of left ventricular hypertrophy through increases in 
sympathetic activity and blood pressure, and the metabolic and 
hormonal abnormalities that characterize insulin resistance. 
The association of obesity and arterial hypertension results in 
increased probability of left ventricular diastolic dysfunction 
and abnormalities in cardiac conduction properties.
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